Recurrent respiratory papillomas (RRP) are benign airway tumors, caused primarily by human papillomaviruses (HPV) types 6 and 11. The disease is characterized by multiple recurrences after surgical removal, with limited effective therapy. To identify novel targets for future therapy, we established transcriptional profiles for actively growing papillomas compared with autologous, clinically normal, laryngeal epithelia (adjacent tissue). Total ribonucleic acid (RNA) from 12 papillomas and 12 adjacent tissues were analyzed by microarray, and the matched sets of tissues compared by paired t test, to identify differentially expressed genes in papilloma tissues while minimizing variations intrinsic to individual patients. Quantitative polymerase chain reaction (PCR) was used to confirm the relative expression levels for a subset of genes. Within the 109 differentially expressed transcripts whose expression varied at least three-fold were two large groups of genes with related functions. The first group consisted of 18 genes related to host defense, including both innate and adaptive immunity. The second group contained 37 genes that likely contribute to growth of papillomas as benign tumors, since the altered pattern of expression also had been reported previously in many cancers. Our results support our previous studies that document a systemic T H 2-like adaptive immune response in RRP, and suggest that there is a role for altered innate immunity in RRP as well. We propose that HPV 6 and 11 infection establishes a tumorigenic microenvironment characterized by alteration of both innate inflammatory signals and adaptive immune responses that prevent effective T H 1-like response, in conjunction with altered expression of numerous genes that regulate cellular growth and differentiation.
INTRODUCTION
Recurrent respiratory papillomatosis (RRP) is caused primarily by human papillomavirus (HPV) types 6 and 11, with all other HPV types causing less than 2% of disease (1, 2) . These viruses induce the growth of benign tumors in the larynx, and less frequently, in the lower respiratory tract. Standard treatment is repeated surgery to remove papillomas that, because of their location in the airway, cause significant morbidity, and on occasion mortality (3, 4) . The interval between surgical intervention varies between patients, ranging from 3 wks to several years (3) . Differences in host immune responses to HPV infection may explain this variability.
An effective immune response to viral infection involves activation of both innate and adaptive immunity, with a balance between T H 1-, T H 2-like, and T H 17-derived chemokines and cytokines, and appropriate signaling through the receptors they bind (5) . We previously reported differences in HPV-specific immune responses by RRP patients and controls that predict disease susceptibility and severity (6) (7) (8) (9) . Peripheral blood mononuclear cells (PBMC) from these patients respond to HPV 6/11 E6 protein by expressing T H 2-like cytokines and interleukin (IL)- 10 (8,9) . Recently, we also identified increased levels of the T H 2-like chemokine CC chemokine ligand (CCL)18 (10) in patient serum. Select class I major histocompatibility complex (MHC) and class II MHC genes are enriched in RRP (6, 7, 11, 12) , and are associated with disease predisposition, and/or disease severity (7, 12) , and correlate with PBMC expression of IFN-γ when challenged with E6 protein (6) . Thus, we pro-posed that the inability of RRP patients to eliminate HPV-infection is likely due to an HPV-specific, T H 2-like/IL-10-biased microenvironment within papillomas that suppresses effective T H 1-like responses, and thereby favors recurrent disease.
The immune system also plays a complex role in regulating the growth and metastasis of malignancies (13, 14) ; however, its role in the development of benign lesions is less well understood. To better understand the expression of specific immune response genes within papilloma tissues, and to identify host genes that are important in the pathophysiology of RRP, we compared the gene expression profiles of paired laryngeal papilloma tissues and autologous adjacent epithelia. We found differences in expression of both innate and adaptive immune response genes, and in many genes associated with a variety of malignancies.
MATERIALS AND METHODS

Patients
Biopsies of papilloma and adjacent epithelia were obtained from patients with RRP undergoing surgery at Long Island Jewish Medical Center following informed consent as approved by the North-Shore Long Island Jewish Health System Institutional Review Board. None of the patients included in our study had high-grade dysplasia in their papillomas. Surgical pathologic studies of these papillomas were performed by the Pathology Department at the Long Island Jewish Medical Center.
RNA Isolation and cRNA Synthesis
Total RNA was extracted immediately (RNeasy spin columns, Qiagen, Valencia, CA, USA), and stored at -70°C. Matched sets yielding 2 μg total RNA from both tissues (n = 12 pairs) were studied. Double stranded cDNA was synthesized from 2 μg of total RNA (Superscript Double-Stranded cDNA Synthesis Kit, Invitrogen, Carlsbad, CA, USA). Total cDNA was used to generate biotinylated cRNA (BioArray High Yield RNA Transcript Labeling Kit, Enzo Life Sciences Inc., Farmingdale, NY, USA).
Microarray and Data Analysis
Twenty μg of fragmented cRNA was hybridized to Human U133A (n = 2) or U133A2.0 (n = 10) microarray chips (Affymetrix, Santa Clara, CA, USA). Samples were processed on a Gene Chip 450 fluidics station (Affymetrix), scanned (Gene Chip 3000 scanner), and analyzed (Affymetrix MAS 5.0 software) according to the manufacturer. Raw data from the arrays is available from the Gene Expression Omnibus (GEO) database (www. ncbi.nlm.nih.gov/projects/geo) as series GSE10935. Data mining was performed using Genesifter software (VizX Labs, Seattle, WA, USA). Log transformed data sets were normalized using gas chromatography robust multi-chip average (GC-RMA). Both "pair wise" analysis between autologous specimens, and group analysis (adjacent tissue versus papilloma) using the false discovery rate algorithm, the Benjamini and Hochberg correction, a fold change of three, and a P < 0.05 were employed. A subsequent filtering step excluded candidate genes that either failed to show a change for half of the matched data sets, or if both normal and papilloma groups were classified as "absent call." Two subsets of biologically relevant genes were further analyzed, namely, immune response genes, and genes associated with malignant transformation. Hierarchical clustering was performed only on the ten paired data sets obtained using the U133A2.0 arrays on all 22,000 probe sets with GeneSpring GX 7.3 software (Silicon Genetics). Briefly, .cel files were transformed using RMA, normalized by setting values below 0.01 to 0.01, normalized to 50 th percentile per chip and to median by gene. Genes with significant differences (P < 0.04) were used to create a condition tree and a relevant gene tree.
Quantitative PCR
To validate microarray results, 16 representative genes from both the immune and tumor-associated groups were examined by quantitative reverse transcriptase PCR (Q-RT-PCR) with gene specific primers (Table 1 ) and a probe from the Universal Probe Library Set (Roche, Mannheim, Germany). IL-1F9 was measured using a Taqman probe. Samples were amplified with an Applied Biosystems 7900 HT thermocycler and results analyzed using the delta-delta C t method.
Association between Gene Expression Fold Change and Disease Severity
Disease severity criteria (3, 8, 9) were used to classify the RRP patients into two separate disease categories: severe, or mild/moderate. These disease severity groups were treated as ordinal variables when calculating disease associations. A quantitative measure of disease severity can be calculated by determining the extent, location, number, and size of the lesions, and dividing that value by the time between surgical interventions measured in d. Individual severity scores range from 0.001 to greater than 0.8. We have empirically established a cut-off at 0.06, with scores exceeding that value being classified as severe, and those below that value as mild/moderate. Our study contained equal numbers of severe and mild/moderate patients. The differences between groups for select genes (upregulated immune and angiogenic genes with fold change ≥ 3.7) was compared using SAS software V9.1.3 (SAS Institute, Cary, NC, USA) and a twotailed, unpaired t test.
Ingenuity Analysis
Data were analyzed by the Ingenuity Pathways Analysis (Ingenuity Systems, www.ingenuity.com). A dataset containing gene identifiers was mapped to its corresponding gene object in the Ingenuity knowledge base using a fold change of > 3.0. These genes (Supplementary Table 1 ) were overlaid onto a global molecular network developed by Ingenuity. Networks were then algorithmically generated based on their connectivity. Pathways were constructed using both direct and indirect relationships. Gene products are represented by shapes, with the biological relationship between two genes represented as a line which is supported by at least one reference from the literature.
All supplementary materials are available online at molmed.org.
RESULTS
Differential Gene Expression Arrays
The use of "paired, autologous tissue sets" helped identify genes that might be obscured in an analysis using nonautologous control tissue, because of intrinsic patient-to-patient variability. The initial pair-wise comparison of papillomas and adjacent tissue identified 364 candidate genes. A filtering step eliminated genes with marginal or absent expression, resulting in 134 unique identifiers comprised of 109 individual candidate genes. Seventy-three genes were upregulated, and 36 others downregulated in papillomas (Supplementary Table 1) .
Hierarchical clustering revealed a clear discrimination between papillomas and adjacent tissues ( Figure 1 ). There was no correlation between the overall transcriptional profile of papillomas from patients with severe disease, in comparison to those from patients with mild/moderate disease, with respect to age, gender, or disease severity. Differentially expressed genes could be divided into three groups: 1) immune response genes; 2) genes that likely play a role in papilloma formation since they also are associated with malignant tumors; and 3) genes whose role in RRP is not yet apparent. There were significant differences between papilloma and adjacent tissue in expression of multiple immune response genes as seen in Figure 2 and the associated Table 2 . The expression pattern of specific genes suggested a local tissue bias away from a robust T H 1 response.
The T H 1-like chemokines CCL19 and CCL21, and the chemo attractants CCL5, CCL14, and CXCL12, which would promote T H 1-like immune infiltrates, all were decreased in papillomas. In contrast, the T H 2-like chemokine CCL20, and the interleukin IL-23, which maintains T H 17 cells, both were increased. Papillomas also showed altered expression of many innate immune genes that could affect the balance between alternative adaptive immune responses. Of these, hBD4, S100A2, S100A7, and S100A12 all were elevated, while ABCA8, required for release of IL-1β, was decreased. Intriguingly, IL-1F9 was elevated markedly in papillomas. This interleukin is an agonist for IL-1Rrp2, a newly described member of the IL-1 receptor family that likely induces an alternative to classical IL-1β signaling. This suggests that the innate immune response is also altered in RRP.
Several other differentially expressed immune response genes appear inconsistent with suppression of a T H 1-like response. While CXCR7, the receptor for CXCL12 was elevated, CXCL12 itself was downregulated. IL-1R2, a decoy receptor that suppresses IL-1β signaling was decreased, but the simultaneous reduction of ABCA8 would limit IL-1β signaling. The pro-inflammatory CXCL1, CXCL6, and CXCL8 (IL-8) all were elevated in papillomas, however these chemokines also have angiogenic functions, that apparently supersede their immunoregulatory function in the pathogenesis of HPV-induced respiratory papillomas. In addition, a number of the innate immune response genes altered in papillomas also are associated with malignancy. These include HSPA8, DARC, S100A2, and S100A7. In every case, the direction of gene expression in papillomas was the same as that reported in malignant tumors.
A large number of non-immune response genes whose expression was altered in the papillomas also have been associated with malignant tumors. These tumor-associated genes included angiogenesis and growth factors, matrixassociated proteins, cell cycle regulators, and tumor suppressors, all of which affect cell growth, differentiation, or survival (Table 3 and Figure 3 ). Changes in expression of other genes, for example, keratins, most likely reflect abnormali- Table 2 show a bias of chemokine and interleukin gene expression in all samples (n = 10). The expression of 9 genes (top), were increased in papillomas, and 8 genes (bottom) were decreased in papillomas relative to the corresponding autologous adjacent tissue. Highly expressed genes are shown as red boxes, low expressed genes are shown as blue boxes, and intermediately expressed genes are shown as yellow boxes. ties in keratinocyte growth and differentiation, but are not important in pathogenesis. In all but three genes in Table 3 , the direction of change in the papillomas was the same as reported by others for malignancies. Thus, a subset of these genes is likely required for growth of both benign and malignant tumors.
The direction and magnitude of the gene fold changes identified by microarray were confirmed by Q-PCR for a subgroup of immune response and tumorassociated genes ( Table 1 ). The direction of change in papillomas was the same as identified by microarray, however, the magnitude of differential expression was greater in general.
Association of Gene Expression and Disease Severity
Since the expression of many immune response and angiogenesis-related genes were altered in papillomas, we asked whether the expression of these genes varied between patients with severe disease as compared with those with mild/ moderate disease. Four genes, IL-1F9 which may determine the type of innate inflammatory response initiated by the host, chemokines CXCL1 and CXCL8, and the growth factor VEGFA all showed more significant elevations in patients with severe disease (Table 4 ). Taken together, elevation in expression of these particular genes in patients with severe RRP suggests that angiogenesis and the regulation of innate inflammatory responses are key factors in RRP pathogenesis. In contrast, the only transcripts which were differentially regulated to a greater degree in patients with mild/moderate disease severity were those for hemoglobin alpha, and hemoglobin beta, which were decreased in the papillomas from patients with less severe disease. The disparity in hemoglobin transcripts might reflect larger numbers of erythrocytes resulting from increased vascularity in papillomas from patients with severe disease.
Pathway Analysis
We utilized the Ingenuity Pathways Analysis to establish relationships between the full set of differentially expressed genes (Supplementary Table 1 ).
The top scoring network (z = 51) was cellular movement/immunological disease/ cellular growth and proliferation with a P value of 10 -15 ( Figure 4A ). This network included 25 of the genes we identified with a central role for VEGFA linked to several growth factors, and NF-κB linked to many cytokines. Moreover, there were associations between VEGFA and NF-κB. The pathway with the second highest significance (z-score) was cancer/cellular movement/reproductive system disease ( Figure 4B ), which revealed prominent involvement of HIF1α, IL-8, and CXCL12, with central importance of p38 MAPK, PI3K, AP1, and Akt consistent with our previous reports of PI3K and p38 pathway activation in papillomas (15, 16) . The identification of these pathways underscores the relationship between gene expression in papillomas induced by HPVs with low oncogenic potential, and polarization of cellular pathways reminiscent of malignancy.
DISCUSSION
We have found altered expression of many immune response genes in papillomas compared with autologous laryngeal epithelium. These differences could contribute to the persistence of infection and recurrence of disease by biasing the papilloma micro-environment away from effective T H 1-like responses. Previously, we reported that PBMCs from RRP patients respond to HPV proteins with increased expression of T H 2-like and regulatory cytokines without adequate expression of IFN-γ (8 to influenza virus (17) . Additionally, CCL19 and CCL21 have been used as adjuvants to enhance CTL responses to tumors (20) . Consistent with this, papillomas do not contain significant numbers of CTLs (9) . In addition, both CCL5 and CCL14 were downregulated in papillomas. CCL14 is a chemo-attractant for both T cells and monocytes (21) , while CCL5 attracts monocytes, memory Thelper cells, and eosinophils (22) . Taken Expression of multiple innate immune response genes also were altered in papillomas. Of particular interest was the elevated expression of IL-1F9 mRNA levels that were significantly higher in patients with severe disease (P = 0.03), suggesting a central role for IL-1F9 in predisposing to severe disease. IL-1F9 binds to IL-1Rrp2 (29) , and is thought to alter innate immune response signaling. Subsequent polarization of the adaptive immune response remains unknown (30) , however, several lines of evidence (31, 32) suggest that IL-1F9 likely induces an alternative to IL-1β signaling. IL-1F9 has been implicated recently in allergen- Altered expression of a small number of genes in papilloma tissues have been reported using qRT-PCR, in situ hybridization, or RNase protection, and many of those changes including hBD4, CXCL8 (34) , and VEGFA (35) also were identified in our analysis, further validating our findings. However, we did not detect elevated levels of survivin mRNA (36) , or transcripts for p16INK4A and p53 (37) . These discrepancies may reflect, in part, our use of matched papilloma and autologous, epithelia pairs, rather than other control tissues.
A number of genes differentially expressed in papillomas have been associated with malignancies, affecting both tumor growth and immune responses. These include cytokines CXCL1, CXCL6, and CXCL8, and VEGFA that can all function as growth and angiogenic factors (38, 39) . Furthermore, increased expression of CXCL1, CXCL8, and VEGFA correlated significantly with severe disease ( Table 4 ), suggesting that angiogenesis, a histological hallmark of RRP, is central to the pathology of this disease. Also evident were reductions in expression of three tumor suppressors (IGFbp5, FHL1, and SPARCL1) and elevated expression of several growth factors (PGF, IGFbp3, and PTHLH). Three members of the S100 family of proteins also were altered in papillomas. These proteins are involved in regulation of numerous cellular processes, including cell growth, differentiation, and progression toward cancer (40) . They all likely play a role in regulating the innate immune response to pathogens. S100 proteins are damageassociated molecular pattern molecules which can function as pro-inflammatory factors of innate immunity (41) . S100A2 has been reported to both promote tumor growth (42) and function as a tumor suppressor gene (40, 43) . S100A7 is overexpressed in breast cancer (44) , epithelial skin tumors (45) , bladder cancer (46) , and is markedly elevated in lesions from psoriasis patients (47), suggesting a role in keratinocyte differentiation, and in regulating the innate immune response associated with epithelial inflammation (46) . S100A12, a potent monocyte chemoattractant (48) that mediates allergic inflammation by Table 3 . Twenty-five of 27 genes that are increased in malignancy (tumor promoters/growth factors) also are increased in papillomas (bottom). Eight of nine genes which are decreased in malignancy (tumor suppressors) also were decreased in papillomas (top). Highly expressed genes are shown as red boxes, low expressed genes are shown as blue boxes, and intermediately expressed genes are shown as yellow boxes.
activating mast cells (49) , also was increased in expression in papillomas. These observations suggest that the less oncogenic HPVs can reprogram cellular pathways similar to that described in some malignancies. Studies are underway to compare HPV 6/11 induced changes with those induced by the oncogenic HPV 16, to identify key cellular processes that distinguish their differential expression in benign versus malignant tumorogenesis. In summary, we have used microarray analysis to identify changes in the transcriptional profiles of papilloma tissue from patients with RRP, as compared with autologous, laryngeal epithelium. We identified several groups of genes that may contribute to the disease process and disease severity. However, genes that are comparably expressed in both tissues would not be detected, even though some also may be important to disease susceptibility and/or severity. Our results support our previous contention that RRP is a disease characterized by a defective T H 1-like response in adaptive immunity. In this communication, we now suggest that altered innate responses to HPV also are present. Our findings may be relevant to other HPVinduced diseases, such as cervical cancer, where oncogenesis complicates and overshadows the inherent immunologic responses made to the more oncogenic HPVs. Our results provide new insight into the disease process associated with RRP, identify for the first time that papillomaviruses with low oncogenic potential can induce gene expression changes characteristically found in malignancies, and identify novel targets for future therapeutic interventions in RRP.
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